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of the divergent ﬁndings. Tenofovir-emtricitabine taken orally for
PrEP has been approved by regulators in the US and Africa, and
is being considered for approval in several African and European
countries. New approaches to chemoprophylaxis are under study,
including the use of vaginal and rectal gels, vaginal rings, and
injectable agents. Because antiretroviral PrEP does not protect
against other sexually transmitted infections (STI), it must be given
as part of a comprehensive sexual health package, which includes
counseling and screening for treatable STI. Other interventions
that can decrease HIV transmission include adult male circumci-
sion of HIV-uninfectedmen, recreational drug treatment, including
access to clean syringes and other drug paraphernalia, and opi-
ate substitution therapy. The advent of new biomedically-based
prevention interventions does not obviate the need for behavioral
interventions, but suggests that counseling interventions should
incorporate reinforcement of medication adherence, as well as risk
reduction counseling.
http://dx.doi.org/10.1016/j.ijid.2016.02.159
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Abstract: HIV care for infants, children and adolescents has
improvedby leaps andbounds.Whereas the landscape twodecades
ago was bleak for children born with HIV who faced inevitable
death, it is now ﬁlled with hope with the ever-increasing access to
anti-retroviral therapy (ART) and care. Coupled with this progress
is the success of prevention ofmother-to-child transmission of HIV
interventions, again with ART, resulting in fewer new infections in
children. Yet, there is a long pathway to be traversed before we can
achieve complete control of pediatric HIV.
Challenges: Being born with HIV or acquiring HIV in childhood
can be devastating, even in the era of ART. Taking ART is a lifelong
practice; the risk of long-term adverse effects is real and lasting,
and children generally have to take ART for an average of 20 years
longer than an adult. This could mean constant monitoring, and in
many cases, life-threatening long-termconsequences. Adolescence
is a time when adherence to any treatment or norms established
earlier is questioned, and HIV care suffers the same fate. Rebellion
and poor adherence to ART results in risk of drug resistance and
treatment failure. Perinatally infected children may face mental
challenges, including learning disabilities and behavioral disorders.
Integrated with the social support offered for these challenges, one
also needs to maintain an honest and respectful discussion with
children about growing up with HIV, including their sexual and
reproductive health.
A hopeful future: The ambitious “90-90-90” goal launched by
UNAIDS in 2014 focuses not just on the 90% of the HIV-infected
population that they aim to diagnose and treat, but also on the 90%
of all treated who will be virologically suppressed. This shift in our
focus frommere volume of care, to actual quality of care in terms of
retentionandsuppression, arekey tooptimalHIVoutcomes.Nelson
Mandela once said, “There can be no keener revelation of a society’s
soul than theway it treats its children.” The know-how and tools that
are available in today’s world offer the global community the very
real and beautiful possibility of controlling pediatric HIV.
http://dx.doi.org/10.1016/j.ijid.2016.02.160
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Abstract: In many resource-limited settings a substantial pro-
portion of HIV-infected patients still commence antiretroviral
therapy (ART) with advanced HIV-related immunosuppression
with lowCD4+T-lymphocyte counts andactiveopportunistic infec-
tions. Such patients are at high risk for developing the immune
reconstitution inﬂammatory syndrome (IRIS) in the ﬁrst weeks to
months of ART as immune responses to opportunistic infection
antigens are rapidly restored resulting in inﬂammatory reactions
directed at antigens of the opportunistic infection. This may result
in hyper-inﬂammatory new presentations of opportunistic infec-
tions or paradoxical deterioration in patients already on treatment
for the opportunistic infection. IRIS is most commonly described in
association with mycobacterial, fungal and viral infections.
Tuberculosis-associated IRIS (TB-IRIS) is the most signiﬁcant
form of the condition encountered in settings where TB endemic.
In a recent meta-analysis, we found that TB-IRIS is reported in
18% (95%CI= 16-21%) of patients starting ART while on TB treat-
ment. Major risk factors for the condition are a low CD4 count,
high HIV viral load, disseminated TB and short interval between
starting TB treatment and ART. A key determining factor thus
appears to be antigen load. Innate and adaptive components of
the immune system have been shown to contribute. A gene tran-
scriptional signature characterised by innate immune signaling
genes distinguished patients who developed TB-IRIS from those
who did not, and was evident within a few days of starting ART
and prior to symptoms. TB-IRIS is characterized by high concentra-
tions of cytokines in peripheral blood, with elevated interleukin-6
identiﬁed consistently across studies. Common clinical presenta-
tions are worsening pulmonary inﬁltrates, enlarging lymph nodes
and abscess formation. Central nervous system involvement (eg.
meningeal inﬂammation, enlarging tuberculomas) may be life-
threatening. The average duration of the condition is 2-3 months,
but a small proportion of cases may have manifestations lasting > 1
year. We demonstrated in a previous clinical trial that prednisone
(starting at 1.5mg/kg/day) reduced hospitalization and improved
symptoms in patients with TB-IRIS. We are currently evaluating
prednisone for prevention of TB-IRIS in high-risk patients with TB
starting ART in a randomized placebo-controlled trial (PredART
trial: https://www.predart.org/site/index).
Cryptococcal IRIS typically presents with recurrent meningitis
in the ﬁrst months of ART, often with associated raised intracranial
pressure. No clinical trials have been conducted, but management
usually involves re-initiation of induction antifungal therapy until
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relapse is excluded, therapeutic lumbar punctures and in severe
cases corticosteroids.
A priority in IRIS research is identifying key inﬂammatory path-
ways that trigger the condition that could be targeted with more
speciﬁc immunotherapy to prevent and/or treat the condition.
http://dx.doi.org/10.1016/j.ijid.2016.02.161
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Abstract: With the advent of antiretroviral therapy (ART), HIV
has shifted to a chronic manageable condition, even in resource-
limited settings. Now, the long-term effects of being on ART and
living with HIV are emerging. These include the adverse effects of
long-term ART and morbidity due to non AIDS complications such
as cardiovascular, hepatic, renal,metabolic and neurocognitive dis-
ease, cancers and ageing as well as complications due to hepatitis
B and C co-infection. Although ﬁrst and second-line antiretrovirals
are available in resource-limited settings, new antiretrovirals are
urgently needed in order to sustain HIV as a chronic manageable
condition. Several clinical trials are underway to eradicateHIV from
reservoirs among patients who are on long-term ART and virologi-
cally suppressed, leading to the hope of eventual eradication of this
virus.
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Abstract: Visceral leishmaniasis is the most severe form of
leishmaniasis, and if untreated, it is fatal. Although pentavalent
antimony (Sbv) ismostwidelyuseddrug for its treatment, but in the
state of Bihar in India and in Nepal moderate to severe resistance
to Sbv led to it being abandoned in the Indian subcontinent. Gov-
ernments of India Nepal and Bangladesh lauched an elimination
initiative for visceral leishmaniasis (VL) in 2005 and oral miltefo-
sine was selected for treatment. Prolonged regimen of almost one
month, frequent gastrointestinal adverse events and teratogenic
potential are major hurdles of the miltefosine treatment leading
to poor compliance. Further, long half life of miltefosine makes
it vulnerable for drug resistance. Recently two important break-
throughs in the treatment of VL provide new perspective in the
control of VL in Indian subcontinent. In a randomized controlled
study over 300 parasitologically conﬁrmed patients were treated
with single dose of 10 mg/kg of liposomal amphotericin B (AmBi-
some, L-AmB). The cure rate was 95.7% which was comparable to
the comparator conventional amphotericin B (96.3%) . In another
phase 3 study which closely followed the single dose study mul-
tiple combinations of the three available drug, L-AmB, miltefosine
and paromomycin were administered between 8-11 days. In this
open labelled, randomized, controlled, non-inferiority trial inBihar,
India, single injection of 5 mg/kg L-AmB and 7-day miltefosine;
L-AmB and 10-day paromomycin; miltefosine and paromomycin
for 10 days were compared with the conventional treatment. The
efﬁcacy rates for all patients enrolled (intent to treat, ITT) were:
amphotericin B 93.0%; L-AmB and miltefosine 97.5% ; L-AmB and
paromomycin 97.5%; miltefosine and paromomycin 98.7% (95.06-
99.78). Combination therapies were well tolerated and had fewer
adverse events than standard treatment. These studies provide
newer vistas in the treatment of VL. Their early implementation
will provide a tremendous boost to the Elimination programme.
http://dx.doi.org/10.1016/j.ijid.2016.02.164
